文献速递姑息放疗与转移瘤放疗物理与技术泌尿生殖与妇科肿瘤放疗

MRI引导立体定向放疗消融治疗腹盆淋巴结转移的多中心分析

Multicenter analysis of MRI-guided, stereotactic body radiotherapy as ablative treatment for lymph nodal metastases of the abdomen and pelvis.
PubMed 文献 · Radiother Oncol · 2025-10-28

这项多中心回顾性研究纳入161例患者共210个腹盆淋巴结转移灶,评估MRI引导在线自适应SBRT的安全性和疗效。中位剂量35 Gy/5次,2年局部控制率85.8%,急性I–III级不良反应分别为23.6%、11.8%、0.6%,提示该技术可获得持久局部控制且毒性可控。

要点

  • MRI引导SBRT治疗腹盆淋巴结转移的2年局部控制率为85.8%。
  • 急性I、II、III级不良反应发生率分别为23.6%、11.8%、0.6%。
  • 2例(1.2%)发生晚期IV级胃肠道溃疡,均为腹腔内大体积靶区。

核心结论

  • MRI引导SBRT治疗腹盆淋巴结转移可获得超过85%的2年持久局部控制率,且毒性谱良好。
  • MRI引导SBRT是淋巴结寡转移消融治疗的可行选择,包括难以治疗的腹腔内靶区。

研究设计与样本

  • 多中心回顾性研究,在四家开展在线自适应MRI引导放疗的机构进行。
  • 纳入2019年5月至2023年10月接受MRI引导SBRT的腹盆淋巴结转移患者161例,共210个转移灶。

主要发现

  • 前列腺癌为最常见组织学类型(45.3%),转移部位为盆腔42.2%、腹膜后39.8%、腹腔内18%。
  • 腹腔内靶区体积显著大于腹膜后或盆腔靶区(p < 0.001)。
  • 中位剂量35 Gy(范围25–50 Gy),中位5次(范围3–10次),不同部位间无差异。
  • 急性I、II、III级不良反应分别占23.6%、11.8%、0.6%;2例(总体1.2%,腹腔内病例5.3%)发生晚期IV级胃肠道溃疡。
  • 单因素分析中,较小靶区体积、前列腺癌组织学、盆腔部位和较高BED与总生存、远隔控制和无进展生存显著相关,但与局部控制率无关。

关键数值与推荐

  • 2年局部控制率为85.8%。
  • 中位剂量35 Gy(范围25–50 Gy),中位5次(范围3–10次)。

临床怎么用

  • 对于腹盆淋巴结寡转移,可考虑MRI引导在线自适应SBRT作为消融治疗选项。
  • 治疗腹腔内大体积靶区时需警惕晚期IV级胃肠道溃疡风险。

局限性

  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Purpose of this study was to assess safety and efficacy of magnetic resonance-imaging (MRI)-guided, stereotactic body radiotherapy (SBRT) for lymph nodal metastases (LNM) of the abdomen and pelvis. METHODS: This multi-center retrospective study was conducted at four institutions practicing online-adaptive, MRI-guided radiotherapy (MRIdian, ViewRay© or Unity MRL, Elekta©). Patients treated with MRI-guided SBRT for pelvic and abdominal LNM were enrolled. Descriptive statistics were performed. Oncological endpoints were calculated and toxicity was assessed. RESULTS: 161 patients treated for 210 lymph node metastases between May 2019 and October 2023 were included. Prostate cancer (45.3 %) was the most frequent histology. The locations of lymph node metastases were pelvic (42.2 %), retro-peritoneal (39.8 %), and intra-peritoneal (18 %) Target volume sizes varied significantly between these different anatomical sites treated, with intra-peritoneal targets being significantly larger (p < 0.001) compared to those retroperitoneal or pelvic. Patients were treated with a median dose of 35 Gy (range 25-50) in a median of five fractions (range 3-10), without differences between localizations. Acute adverse effects of grade I, II and III occurred in 23.6 %, 11.8 %, and 0.6 % of the patients, respectively. Two patients (1.2 % overall and 5.3 % of intra-abdominal cases) experienced late adverse events, both grade IV gastro-intestinal ulceration four and twelve months after irradiation of bulky intra-peritoneal LNM. The 2-years local control-rate was 85.8 %. In univariate analyses, smaller target-volumes, prostate histology, pelvic localization, and higher BED were statistically significantly associated with improved overall survival, distant control rates and freedom from progression but not with local control rates. CONCLUSION: MRI-guided SBRT for abdominal and pelvic LNM achieved durable local tumor control rates of over 85% after two years and was associated with a favorable toxicity profile. MR-guided SBRT is a valid option for ablative treatment of nodal oligometastases, even for the difficult to treat intra-abdominal targets.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. von der Grün J, Regnery S, Hörner-Rieber J, et al. Multicenter analysis of MRI-guided, stereotactic body radiotherapy as ablative treatment for lymph nodal metastases of the abdomen and pelvis. Radiother Oncol. 2025. PMID: 41167279. doi:10.1016/j.radonc.2025.111237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。